Exchange: NASDAQ·Updated 03:04 PM EDT
AVTX logo

AVTX Avalo Therapeutics Inc

$19.20
$0.20
(1.05%)
Today
Reported EarningsAug 6
Mkt Cap$1.02B
Vol390,414.00

About AVTX

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
36

Bearish Sentiment

How do you feel about AVTX?

Advertisement|Remove ads.